Ivermectin and Mebendazole in Cancer Treatment

Half, about half, 48% did

report their cancer disappeared or the tumor shrank,

and 32% or 36% reported

that their cancer stabilized. So it wasn't spreading, it was

staying stable. And so that's what makes up the 84.4%

clinical benefit ratio. This was the single largest

human study on ivermectin and mebendazole in cancer

patients. We had 200 cancer patients with active

cancer. 36% had active metastatic cancer.

These cancer patients were prescribed off-label ivermectin

and mebendazole, and then after six months,

84.4% of them did report to have

benefited in their cancer. It's extremely promising, and now

we need double-blind, randomized, placebo-controlled trials.

This study has to serve as the springboard.

They have to be initiated immediately.